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Hypoxic cells in animal and human tumours are thought to arise
primarily through two distinct mechanisms. The first is termed
chronic, or diffusion-limited, hypoxia. This mechanism was first
proposed by Thomlinson and Gray (1955) who observed viable
cells around regions of oxygen supply in lung tumours, and
necrosis at distances of around 150 mm consistent with the limit of
oxygen diffusion combined with oxygen consumption rates in
tumour tissue. The second mechanism is through transient changes
in blood-flow (Sutherland and Franko, 1980; Chaplin et al, 1986;
Brown, 1979). With this acute form of hypoxia, the affected cells
may have a greater chance of viability because hypoxia is shorter
and temporary. This could pose problems since hypoxia-mediated
selection of cells with diminished apoptotic potential could
occur, possibly accounting for resistance to radiotherapy and
chemotherapy-induced apoptosis (Chaplin et al, 1986; 1987).
Chronically, hypoxic cells are often energy-deficient and conse-
quently less capable of DNA repair, rendering them sensitive to
radiation (Durand, 1983; Spiro et al, 1984), and by inference, to
other DNA-damaging agents. This would reduce their impact
in determining the outcome of therapy. Acutely hypoxic cells,
however, due to their transient nature, may be less nutrient- and
energy-depleted, well capable of repair, and therefore resistant to
therapy, both because of their hypoxic state (radiation) and their
temporary removal from drug supply (chemotherapy). This
emphasizes the need to include these cells in measurements of
total hypoxia in human tumours.
There is now a large body of evidence in animal tumours
showing that blood-flow in tumour vessels is disordered, shows
wide variations in flow rate, and can temporarily or permanently
cease, or even reverse in direction (Brown, 1979; Reinhold and
van den Berg-Blok, 1983; Chaplin et al, 1986). This has been
shown with a variety of techniques including implanted ‘sand-
wich’ chambers, injecting two intravascular markers separated in
time (the mismatch technique) (Chaplin et al, 1987; Trotter et al,
1989b) and by using perfusion markers such as the Hoechst dye
H33342 together with immunostaining for vessels (Bernsen et al,
1995; van Geel et al, 1996). The fraction of perfused vessels in
animal tumours is often considerably less than 100%. Temporary
flow reduction or cessation will almost certainly lead to a transient
increase in hypoxia for those tumour cells supplied by the vessel
(Kimura et al, 1996; Dewhirst, 1998).
Several markers are available for measuring vascular perfusion
in animal tumours, including labelled dextrans, albumins, and
fluorescent dyes such as Hoechst 33342 and DiOC7 (Trotter et al,
1989b). The marker is injected intravenously and a sample taken
within minutes. High-molecular-weight markers (albumins and
dextrans) are found largely intravascularly at these short sampling
times, while Hoechst dyes diffuse out of vessels but bind in
DNA of cells surrounding a vessel, thereby delineating areas of
perfusion. Most of these are not suitable for human use for toxicity
reasons, although labelled dextrans have been used with local
administration (Huber et al, 1984; Bollinger, 1993).
Thymidine analogues such as iodo- and bromo-deoxyuridine
(IdUrd, BrUrd) could be useful as indirect perfusion indicators.
Both analogues are approved for clinical use and have undergone
widespread testing and application as kinetic markers in human
cancer (Begg, 1995; Begg et al, 1999). The presence and intensity
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undergoing DNA synthesis, but also on analogue supply. In histo-
logical sections of both animal and human tumours, areas of light
or even no labelling are not uncommon. These areas usually
contain cells appearing normal and viable, and which will some-
times stain positively for intrinsic proliferation markers like
histone H3 (Kotelnikov et al, 1997). A plausible explanation is
that blood-flow is temporarily reduced in these areas, reducing or
eliminating supply of the thymidine analogue. In the present study,
we have investigated whether variations in IdUrd labelling can
indirectly assess blood-vessel function. The advantage of using
thymidine analogues is that they are already used on a wide scale
in the clinic at non-toxic doses for cell kinetic studies, obviating
the need for new drug development.
MATERIALS AND METHODS
Tumour model
Female C3H/Km mice, weighing 20–30 g, were used throughout.
The RIF1 sarcoma was maintained according to recommended
procedures of Twentyman et al (1980), involving alternating in
vivo and in vitro passaging. 105 cells were inoculated subcuta-
neously on the lower dorsum of mice and grown until they reached
a size of 8 ± 1 mm mean diameter.
Drugs
IdUrd (5-iodo-2¢-deoxyuridine; Sigma, Zwijndrecht, The Nether-
lands) was dissolved in a sterile saline solution and injected
intraperitoneally (i.p.) at a dose of 3, 10 or 30 mg kg–1.
Hydralazine and nicotinamide (Sigma) were dissolved in sterile
saline and injected intraperitoneally (i.p.) at a dose of 5 mg kg–1
(hydralazine) or 1000 mg kg–1 (nicotinamide). The hydralazine
dose was chosen because this dose has been shown to reduce
perfusion in a murine tumour model (Trotter et al, 1989a).
Similarly, the nicotinamide dose was chosen as that showing
perfusion improvement in animal tumour models (Honess and
Bleehen, 1995). Both drugs were freshly prepared before each
experiment. IdUrd was injected 20 min after hydralazine or
60 min after nicotinamide. Mice were then sacrificed either 10 or
30 min after IdUrd injection. Tumours were excised and fixed
in 4% buffered formaldehyde, pH 7.0, for 24 h.
IdUrd was also compared with Hoechst 33342 as a direct perfu-
sion marker. IdUrd was injected at a dose of 30 mg kg–1 i.p.,
followed 28 min later by 0.1 ml Hoechst 33342 (9 mg ml–1), given
i.v. in the tail vein. The mice were sacrificed 2 min later, the
tumour immediately excised and snap-frozen in liquid nitrogen.
Antibodies
Monoclonal antibodies were used against a surface marker on
endothelial cells and against IdUrd. The first was a rat anti-mouse
CD31 antibody clone MEC 13.3, dilution 1/200 (PharMingen,
Leiden, The Netherlands), while the second was a mouse anti-
BrdUrd, dilution 1/50 (Central Laboratory for Blood Transfusion
(CLB), Amsterdam, The Netherlands). For the comparison with
Hoechst 33342 on frozen sections, IdUrd labelling was visualized
using a FITC-labelled goat anti-mouse antibody (Sigma) at a 1/50
dilution.
Immunohistochemistry
Paraffin sections (4 mm) were cut and transferred to silane-coated
glass slides (3-aminopropyltriethoxy silane, 2% in absolute
ethanol, 5 s). Endogenous peroxidase activity was blocked with
0.3% hydrogen peroxide in methanol (30 min at RT). Microwave
treatment was used for IdUrd, and 0.1% pronase for CD31, as
antigen-retrieval methods. To reduce non-specific staining, Protein
Block Serum-Free (undiluted, 30 min at room temperature; ITK,
Uithoorn, The Netherlands) was used. After removing the protein
block, the slides were incubated with either the anti-CD31
(overnight, 4°C), or the anti-BrdUrd antibodies (2 h at 37°C). A
biotinylated second antibody was then added, rabbit anti-rat for
CD31 (ITK) and goat anti-mouse for BRdU (Sigma), together
with an avidin–biotin–peroxidase complex (Vectastain ABC Kit,
Vector) for 30 min at room temperature. For the CD31 staining, an
amplification step (Tyramide Signal Amplification Kit Indirect,
NEN Life Science, The Netherlands) was used after incubation
with the biotinylated second antibody. After washing with PBS,
the peroxidase activity was detected either with a diaminobenz-
amide (DAB) (brown, for IdUrd) or with a DAB/nickel solution
(black, for CD31) in distilled water until suitable staining devel-
oped (DAB substrate kit for peroxidase, Vector). Slides were
rinsed with tap water, lightly counterstained with haematoxylin for
visualization of tissue architecture, dehydrated (alcohol, xylol) and
mounted with DePeX mounting medium (BDH).
For the IdUrd/Hoechst comparison, 4 mm frozen sections were
cut and either stained with the anti-BrdUrd mouse antibody
followed by a FITC-labelled anti-mouse second antibody, or left
unstained, allowing visualization of the Hoechst dye under UV
excitation.
Flow cytometry
The staining procedure for IdUrd labelling has been published
previously (Begg et al, 1988). Briefly, ethanol-fixed pieces were
first incubated in a pepsin solution (0.4, 20 min, RT), incubated
with a mouse anti-BrdUrd monoclonal antibody (CLB, 30 min,
RT), followed by incubation with a FITC-conjugated second anti-
body (30 min, RT, goat anti-mouse; Sigma). For staining DNA,
propidium iodide (10 mg ml–1) plus RNase (0.2 mg ml–1, 13.4
Kunitz units ml–1) was used. Throughout the staining, the cells
were washed between each step with diluting buffer consisting of
PBS plus 0.1% bovine serum albumin and 0.05% Tween 20. All
samples were analysed on a FACScan flow cytometer (Becton
Dickinson) with an argon laser operating at 488 nm and 15 mW.
Alignment and standardization of the instrument was performed
using fluorescent beads. Emission filters were 515–545 nm Band
Pass filter (green; IdUrd) and 650 nm Long Pass filter (red; DNA).
20 000 cells were analysed for each sample. The green fluores-
cence signal (IdUrd) was displayed on a log scale and the red
fluorescence (DNA) on a linear scale.
Image analysis
Digitized images of the CD31 and parallel IdUrd sections were
processed with a macro written in Adobe Photoshop which carried
out the following operations: contrast stretch to use full range of
grey values, convert image from 12-bit to 8-bit to visualize image
on computer monitor, sharpen image (using unsharp mask filter),
duotone to make blood vessels red, or contrast enhance for IdUrd
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plastic transparent sheets using a Tektronix Phaser 240 after
scaling the image to 50%. A tumour section, comprising up to 16
adjacent images captured using the microscope scanning stage,
was reconstructed on the transparencies by taping adjacent images
together. This was done separately for CD31 and IdUrd. The
reconstructed images of the CD31-stained section were then over-
layed on those for IdUrd and observed using a light box. The
CD31 and IdUrd layers were then matched using two features: the
form of the tumour edges and the pattern of the large vessels which
were visible on both IdUrd and CD31 sections. Sometimes a
match could be obtained in one area but not in another without
altering the relative positions of the two reconstructed images.
This could be due to folds or breaks in one of the sections, or slight
differences in shrinkage during processing. In general, matching
was clear, with only slight adjustments needed for the different
areas. A grid, printed out on a transparency, was subsequently
overlayed on the composite image to guide the scoring of vessels.
Each vessel was scored on the number of IdUrd-labelled cells in
its vicinity on a scale from 0–5, 0 being no label and 5 corre-
sponding to the maximum labelling density seen in that tumour. A
vessel with labelling on one side but not on the other was scored as
half of the labelling density on the positive side, e.g. label meriting
a score of 4 would only be scored as 2 if occurring on one side
only. The distance from a vessel in which labelling was scored was
approximately equal to eight cell diameters. Each branch of a
branched vessel was scored separately.
For the comparison of IdUrd and Hoechst labelling, consecutive
images were captured using the computer driven microscope stage
as described above. After correcting for illumination differences
across each image by background subtraction, a composite image
of the tumour was reconstructed. The composite image was then
‘inverted’ to convert from a dark to a light background, and from
light objects (IdUdR labelled cells or Hoechst fluorescence), to
dark-labelled objects.
RESULTS
Flow cytometry
To investigate the effect of blood-flow manipulation on IdUrd
labelling, mice with subcutaneous RIF1 tumours were injected with
hydralazine, nicotinamide or physiological saline and 20–60 min
later injected with IdUrd. Three separate experiments were carried
out, investigating IdUrd dosage, time between IdUrd injection and
sacrifice, and time between hydralazine and IdUrd. Results of the
first experiment investigating different IdUrd doses of 3–30 mg kg–1
employing an IdUrd-sacrifice time of 30 min are shown in Figure 1.
In control mice, neither labelling index (LI) nor labelling intensity
(fluorescence ratio, FR) changed significantly with increasing IdUrd
doses (Figure 1 top and middle panels, left bars). Hydralazine
appeared to cause decreases in both LI and FR, which was most
obvious at the lowest IdUrd dose. However, these changes were not
statistically significant (P > 0.05, t-test). In this experiment there
was a 60 min interval between hydralazine and IdUrd, which was
reduced in subsequent experiments (see below). Variation in fluores-
cence intensity of IdUrd labelling for each tumour, expressed as the
coefficient of variation (CV) of green fluorescence, was also investi-
gated. The CV was decreased after nicotinamide, although not
significantly (t-test). Hydralazine had little effect.
In the second experiment, we investigated lower IdUrd doses
down to 0.3 mg kg–1 and shorter times between IdUrd and sacri-
fice, following the reasoning that differences dependent on blood-
flow may be more evident during the early uptake phase and at
non-saturating IdUrd concentrations. Using a 10 min IdUrd-
sacrifice interval (Figure 2, top panels), both LI and FR increased
in control mice with increasing IdUrd dose from 0.3–3 mg kg–1.
The interval between hydralazine and IdUrd was decreased from
IdUrd as perfusion marker 901
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Figure 1 IdUrd labelling index, labelling intensity (fluorescence ratio
labelled : unlabelled cells) and variation in labelling intensity per tumour (CV)
of RIF1 tumours for control mice or mice treated with hydralazine to reduce
perfusion or nicotinamide to increase it. Mice were given 3, 10 or 30 mg kg–1
IdUrd. Errors are ± SD, three mice per group. Some combinations were not
done, namely: 10 mg kg–1 IdUrd for both hydralazine and nicotinamide and
3 mg kg–1 for nicotinamide60–20 min, based on optimal blood-flow reduction data in mouse
tumours reported in the literature (Trotter et al, 1989a).
Hydralazine clearly reduced both numbers and intensities of
labelled cells. No obvious increase in either LI or FR was evident
after nicotinamide. At the 30 min sacrifice time, LI remained
constant with dose, but FR increased approximately proportionally
to IdUrd dose. Suppressive effects of hydralazine were somewhat
less evident than in the 10 min data. Nicotinamide caused no
increase in labelling, or even a slight decrease.
The protocol for the third experiment followed the first, but
used an optimum hydralazine-IdUrd interval of 20 min and did not
exclude any group combinations. The results (Figure 3) confirmed
the data of the first two experiments in showing a distinct suppres-
sive effect of hydralazine and little effect of nicotinamide. Pooling
times and doses for this last more extensive experiment, the mean
LIs for the control, nicotinamide and hydralazine groups were
15.0 ± 2.5, 16.3 ± 2.1, and 6.7 ± 3.8 respectively. The mean FRs
for the control, nicotinamide and hydralazine groups were
42.0  ± 11.2, 40.0 ± 17.4, and 21.7 ± 7.1 respectively (errors ± 1
SD,  n = 18–19). For both LI and FR, the difference between
control hydralazine groups was significant (P < 0.001).
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Figure 2 IdUrd labelling index and labelling intensity of RIF1 tumours in
control mice or mice treated with hydralazine to reduce perfusion or
nicotinamide to increase it. Mice were given 0.3, 1 or 3 mg kg–1 IdUrd (see
legend upper right) and sacrificed 10 min (upper panels) or 30 min (lower
panels) after IdUrd. Errors represent range, two mice per group
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Figure 4 Examples of images of immunohistochemical labelling with IdUrd
in control RIF1 tumours (A) or in those treated with hydralazine (B) or
nicotinamide (C) (magnification ´ 25). Decreased labelling after hydralazine
and a tendency for more uniform labelling after nicotinamide is evident
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Figure 3 IdUrd labelling index (left) and intensity (right) of RIF1 tumours in
control mice or mice treated with hydralazine or nicotinamide. Mice were
given 3, 10 or 30 mg kg–1 IdUrd and sacrificed 10 or 30 min after IdUrd.
Errors are ± SD, 3–4 mice per groupImage analysis
Images of immunohistochemically stained slides for IdUrd and
vasculature were digitized and analysed for labelling variations
around individual vessels. IdUrd labelling patterns showed some
heterogeneity in control tumours (Figure 4A) which appeared to
become more homogeneous after nicotinamide treatment (Figure
4C). After hydralazine, labelling was clearly reduced (Figure 4B).
To quantify labelling, each vessel was scored on a scale of 0–5,
indicating no–high labelling, and was achieved by matching
adjacent sections of vascular and IdUrd staining (see Methods).
Histograms of the scores showed an approximate normal distribu-
tion, with some variation from area to area within control tumours.
Of note was the fact that significant but small numbers of vessels
were observed with no label in their vicinity.
In order to assess reproducibility of scoring, one area of the
tumour was rescored approximately 4 weeks after the first scoring.
Although there were minor differences (Figure 5), the repro-
ducibility was good. In the first scoring session, 109 vessels were
noted and scored, while in the second, 107 were found. This was
also regarded as good agreement.
Next and most importantly, a comparison of tumours was made
under conditions of reduced or increased perfusion (Figure 6).
Mice from the experiment shown in Figure 3 were used, which
received an IdUrd dose of 30 mg kg–1 and which were sacrificed
30 min later. After hydralazine (Figure 6B), there was a large
increase in the fraction of vessels with no surrounding IdUrd
labelling, reaching a value close to 50% compared with 3% of
vessels in control tumours. Nicotinamide showed a shift to the
right compared with control tumours, and no vessels were found
together with a complete absence of IdUrd labelling, indicating
better perfusion after administration of this drug. The median
values of the vessel scores were 2.0, 0.5 and 3.5 for control,
hydralazine and nicotinamide respectively.
The approach was further validated by directly comparing
IdUrd labelling patterns with those after Hoechst injection, a direct
perfusion marker. Adjacent sections were either stained with an
anti-IdUrd antibody or left unstained, allowing visualization of the
blue fluorescent Hoechst dye under UV excitation. A series of
consecutive images was then captured using a computer-controlled
stepping microscope stage and a ´ 10 objective. Figure 7 shows
tumour sections reconstructed from the separate images. The
IdUrd staining (Figure 7A) shows considerable heterogeneity of
labelling, with little or no label near the tumour centre. The
Hoechst images (Figure 7B) show perfused blood vessels mainly
on the periphery of the tumour, with little visible perfusion in the
tumour centre. The similarity of these patterns is consistent with
the hypothesis that IdUrd labelling can monitor tumour perfusion.
DISCUSSION
The present data show that changes in vascular perfusion in this
mouse tumour model are reflected by changes in labelling of the
IdUrd as perfusion marker 903
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Figure 5 Reproducibility of IdUrd scoring around vessels. The same
microscope fields in RIF1 tumour sections were scored on two occasions
separated by several weeks by the same observers
Figure 6 Histograms of IdUrd labelling around vessels for control RIF1
tumours (A) or tumours treated with hydralazine (B) or nicotinamide (C). A
clear increase in low IdUrd scores is seen after hydralazine and a decrease
after nicotinamide. The number of vessels scored were 733, 633 and 274 for
control, hydralazine and nicotinamide respectively
Figure 7 Comparison of IdUrd labelling (A) with Hoechst 3342 perfusion
(B) from adjacent frozen sections of a RIF1 tumour. Each section is a
composite of contiguous images captured using a ´ 10 objective. Similar
labelling patterns are evident for both labels
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ABthymidine analogue IdUrd. This was found by both flow cytom-
etry, where the whole tumour is investigated but where geograph-
ical information is lost, and by image analysis, where individual
vessels can be studied. The most clear effects were seen with
hydralazine, in which reductions in both numbers and intensities
of labelling were observed, and where the number of vessels with
no surrounding IdUrd labelling increased dramatically. This is
consistent with the study of Trotter and colleagues (1989a) who
showed a large increase in vessels showing no perfusion after
hydralazine treatment in the SCCVII murine tumour using a
double fluorescent marker staining technique.
Nicotinamide showed less obvious effects with flow cytometry,
although image analysis showed fewer vessels with no/low
surrounding IdUrd, indicating an improvement in perfusion. The
RIF1 tumour is relatively well perfused in untreated animals, as
evidenced from the low proportion (3%) of vessels with no label,
although intratumoural perfusion variations have been reported for
this tumour (van Geel et al, 1996). Blood-flow studies have shown
little effect of nicotinamide in RIF1 tumours (Honess and Bleehen,
1993; 1995), although nicotinamide alone at the dose used here
has been shown to sensitize the hypoxic tail of the single-dose
radiation survival curve, indicating perfusion and oxygenation
improvements (Horsman et al, 1987). The studies are consistent
with little increase in total blood-flow but a redistribution after
nicotinamide, leading to fewer closed or low-flow vessels and a
subsequent reduction in the hypoxic fraction. This was seen in our
study by a right shift of the IdUrd labelling histogram around
vessels.
The correspondence between IdUrd supply and labelling inten-
sity will depend on the IdUrd dose-range, and from the present
data is apparently linear only at doses less than 3 mg kg–1. The
labelling index, however, remained remarkably constant over the
wide dose-range of 0.3–30 mg kg–1. The drop in LI after
hydralazine with an IdUrd dose of 30 mg kg–1 therefore implies a
perfusion decrease of a factor of over 100, and probably a total
shut-down in many vessels, consistent with the Trotter study
(Trotter et al, 1989a). This also implies that perfusion decreases
could be detected earlier from labelling intensity than from
labelling index changes. If the IdUrd supply is only temporarily
decreased, the cells will probably still express proteins responsible
for, or associated with, cell-cycle progression, such as PCNA,
cyclin A and Ki67. A refinement of the proposed technique would
therefore be to double-stain for IdUrd and an endogenous prolifer-
ation marker IdUrd-negative but Ki67-positive regions would
indicate a temporary perfusion decrease.
IdUrd labelling may not always mirror perfusion. Firstly, in a
cluster of vessels in close proximity, one vessel could be poorly or
non-perfused but still have IdUrd labelling around it through
supply from neighbouring vessels. This is unlikely to be a problem
when making the link with hypoxia, since oxygen will probably
also be supplied from the surrounding vessels, preventing local
hypoxia. Lack of labelling around a vessel could also occur if there
were proliferating cells but no S-phase cells in the vicinity of a
vessel. This is statistically unlikely with LIs typically found in
many human tumours. Thirdly, resumption of flow in a vessel
closed for sufficient time to halt proliferation of tumour cells
around it would supply IdUrd but no labelling would occur. The
frequency of such an occurrence is not known. Lastly, not all
vessels will be stained, as judged from areas showing considerable
IdUrd labelling but no visible vessels. Whether these missed, and
therefore unscored, vessels show a different range of perfusion
than the stained vessels remains to be determined.
The scoring of IdUrd labelling around vessels in the manner
described here has a subjective element and is semi-quantitative.
Several factors influence the scoring including, first and foremost,
the definition of a vessel. In this study, we scored all branches of a
complex structure as separate vessels, based on the observation
that labelling around branches was often less than around the main
vessel. Secondly, to define the maximum scoring we scanned the
tumour and picked out areas of maximum labelling which were
assigned the score 5. This would vary between tumours, and so
remains a relative scale. The scoring will be most accurate in high-
LI tumours and least accurate in low-LI tumours. The mean LI in
the present tumour was around 15%. Human head and neck
tumours typically have an LI around 12% (Begg et al, 1999),
making such scoring feasible on this type of human tumour.
Thirdly, the distance from a vessel included in the score was 5–6
cell diameters, based on observations on labelling around rela-
tively isolated vessels. Despite the subjective element, the method
proved surprisingly robust in the reproducibility test. The develop-
ment of a suitable double-staining protocol in which vessels and
IdUrd could be stained with different colours in the same section
would avoid the necessity of matching and thus improve and speed
up the technique.
In conclusion, the use of an exogenous marker originally
designed for cell kinetic studies appears to provide additional
information reflecting local perfusion variations. As such, it could
provide a useful supplement to methods investigating human
tumour hypoxia. Several centres, including our own, are
combining hypoxia measurement techniques, e.g. administration
of bioreductive marker drugs, with I- or Br-dUrd, in order to
additionally measure cell kinetic parameters. Application of the
technique described here would also allow estimates of perfusion-
limited hypoxia from the fraction of vessels with little or no
analogue labelling around them.
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